CoChat

The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence.

Hester, Robert, Lee, Nicole, Pennay, Amy, Nielsen, Suzi, Ferris, Jason · 2010 · Experimental and Clinical Psychopharmacology

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

The cognitive benefits of modafinil to patients undergoing 7-day inpatient withdrawal from methamphetamine (MA) dependence were examined as part of a double-blind, randomized, placebo-controlled pilot trial. Recent evidence has identified modafinil-related improvements in treatment outcomes for MA-dependent patients; however, the benefits to cognition function, which is critical to treatment success but known to be impaired, has yet to be examined. The first 20 participants recruited to the study were administered either 200 mg of modafinil (once daily) or placebo, and a neuropsychological test battery (including an MA version of the emotional Stroop task) at admission (n = 17) and discharge (n = 14). Follow-up interviews were conducted at 1-month postdischarge (n = 13). After participant withdrawals (3 in each group), treatment was associated with a significant improvement in immediate verbal memory recall and nonsignificant trend toward improvement on executive function and delayed memory tasks. No benefit was seen for measures of verbal learning, visual memory, processing speed, or verbal fluency. All participants showed a significant attentional bias for MA-related stimuli on the emotional Stroop task. The magnitude of bias predicted both retention in treatment and relapse potential at follow-up but was not significantly ameliorated by modafinil treatment. While nonsignificant, the effect sizes of modafinil-related improvements in executive function and memory were consistent with those found in more robustly powered studies of cognitive benefits in attention-deficit/hyperactivity disorder and schizophrenia, supporting the need for further research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1037/a0021791

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

Metadata

Authors
Hester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J.
Affiliations
The University of Melbourne (AU)
Venue
Experimental and Clinical Psychopharmacology
Published
2010-12
Volume
18
Issue
6
Pages
489-497
ISSN
  • 1064-1297 (ISSN-L)
  • 1936-2293
OpenAlex
W2134746607
Cited by
42
References
68
Citations by year
2025: 1 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 6 · 2018: 1 · 2017: 3 · 2016: 5 · 2015: 1 · 2014: 2 · 2013: 6 · 2012: 3
FWCI
2.56
Type
journal article
Language
en
Open access
closed
Locations
  • Experimental and Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Australian Government Department of Health and Ageing
  • National Health and Medical Research Council (519730)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Keywords
modafinil, methamphetamine dependence, attentional bias, emotional Stroop task, neuropsychological performance, verbal memory, executive function, treatment retention, relapse, cognitive impairment
MeSH terms
Modafinil, Adult, Central Nervous System Stimulants, Attention, Benzhydryl Compounds, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Memory, Methamphetamine, Middle Aged, Neuropsychological Tests, Pilot Projects, Recurrence, Substance Withdrawal Syndrome, Treatment Outcome, Amphetamine-Related Disorders, Young Adult, Executive Function, Stroop Test

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.